RIPK1 and metabolic dysfunction-associated steatohepatitis: Importantly, circulating concentrations of RIP1 and RIP3 distinguished patients with alcohol-associated hepatitis (AH) from healthy controls, as well as from patients with metabolic-associated steatohepatitis (MASH; formerly known as NASH) (Miyata et al, 2021) and RIP3, but not RIP1, is a promising prognostic indicator for patients with AH (Miyata et al, 2021).